

# PAAT

Programme  
Against  
African  
Trypanosomiasis



ISSN 1812-2442

## INDEX

Volume 30

Parts 1–2 (2007)

Numbers 14020–14340



TSETSE AND TRYPANOSOMIASIS INFORMATION



**DFID**

Department for  
International  
Development



# PAAT

Programme  
Against  
African  
Trypanosomiasis

## INDEX

Volume 30  
Parts 1–2 (2007)  
Numbers 14020–14340

TSETSE AND TRYPANOSOMIASIS INFORMATION

Edited by  
**James Dargie**  
Bisamberg  
Austria

The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned.

All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to:

Chief

Electronic Publishing Policy and Support Branch

Communication Division

FAO

Viale delle Terme di Caracalla, 00153 Rome, Italy

or by e-mail to:

[copyright@fao.org](mailto:copyright@fao.org)

## TSETSE AND TRYPANOSOMIASIS INFORMATION

The Tsetse and Trypanosomiasis Information periodical has been established to disseminate current information on all aspects of tsetse and trypanosomiasis research and control to institutions and individuals involved in the problems of African trypanosomiasis. This service forms an integral part of the Programme Against African Trypanosomiasis (PAAT) and is jointly sponsored by the Food and Agriculture Organization of the United Nations (FAO), the International Atomic Energy Agency (IAEA), the Inter-African Bureau for Animal Resources of the African Union (AU-IBAR), the World Health Organization (WHO), the Research Department for Livestock Production and Veterinary Medicine of the Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD-EMVT), the British Government's Department for International Development (DFID) and the Institute of Tropical Medicine, Antwerp (ITM).

The half-yearly periodical is prepared for publication, in both English and French editions, by the Food and Agriculture Organization of the United Nations. Each annual volume consists of two parts and an index. Subscription is free for all recipients engaged in trypanosomiasis research and control, and requests for enrolment may be sent to: Ms Maria Grazia Solari, AGAH, FAO, Viale delle Terme di Caracalla, 00153 Rome, Italy (fax +39 06 5705 5749; e-mail [MariaGrazia.Solari@fao.org](mailto:MariaGrazia.Solari@fao.org)).

Since the value of this information service depends to a great extent on the receipt of relevant material from research workers, campaign planners and organisers and field workers themselves, readers are requested to submit news items and copies of scientific papers and reports to the Editor: Dr James D. Dargie, Brunnstubengasse 43, 2102 Bisamberg, Austria (tel. +43 2262 61735; e-mail [j.dargie@aon.at](mailto:j.dargie@aon.at)).

We regret that we are unable to supply photocopies of the papers quoted in the quarterly.

### Distribution dates and copy deadlines

	Copy deadline for news items	Distribution (English and French editions)
<i>Part 1</i>	15 April	July/August
<i>Part 2</i>	15 October	January/February

## CONTENTS

	<i>Page</i>
SUBJECT INDEX	1
AUTHOR INDEX	22

## SUBJECT INDEX

Numbers refer to the abstract and bibliographic reference numbers appearing in the *Tsetse and Trypanosomiasis Information*, volume 30 part 1(2007) and *Tsetse and Trypanosomiasis Information* 30 part 2 (2007).

### **acaricides**

footbath treatment to control  
*Amblyomma variegatum*, 14030

### **acivicin**

effect on *T. brucei* in mice, 14108  
homologous recombination, 14131

### ***Agilus planipennis*** 14182

*Albizia zygia* *see* drugs, natural products

### **alpha 2 macroglobulin**

kinetics of production in rats infected  
with *T. lewisi*, 14245

### **alphacypermethrin** 14041

**alpha-difluoromethylornithine (DFMO)**  
*see* drugs and trypanosome infection in  
humans

### ***Amblyomma variegatum*** 14030

**American trypanosomiasis** *see*  
trypanosomiasis in humans (South  
America)

### **amplified fragment length**

**polymorphism (AFLP)** *see* genetic  
characterization methods

**anaemia** 14082, 14085, 14090, 14099,  
14101, 14235, 14238

### **Anaplasmosis**

ELISA for detection, 14094

**animal models** *see* trypanosomiasis in  
humans

***Annona senegalensis*** *see* drugs, natural  
products

### ***Anopheles gambiae***

comparison of laboratory-reared and  
wild insects, 14175

### ***Anoplophora glabripennis*** 14182

**antibodies** *see also* immune responses

egg yolk (IgY) 14046  
IgM monoclonal, 14093  
IgM and mice immunity, 14095  
IgG, 14051

**antigenic variation** *see* immune response  
and *Trypanosoma brucei*

**apolipoprotein L-I (APOLI)** *see* immune

responses and trypanosomiasis in  
humans

**area of low pest prevalence** 14169

### **area-wide integrated pest management**

agricultural trade, 14169  
commercialization, 14176  
crop planting, 14182  
feasibility studies, 14176  
GIS, global positioning systems and  
remote sensing, 14168  
insecticide treatments, 14182  
lessons from programmes with SIT  
component, 14188  
sterile insect technique (SIT) 14182  
strategies, 14176  
successes and failures, 14176

### **Argentina**

monoclonal antibody for *T. evansi*  
infections in horses, 14093

**arsonoliposomes** *see also* drugs  
trypanocidal activity of, 14283

### **attacin**

refractoriness of tsetse to infection,  
14195

### ***Babesia bovis*, *B. bigemina*, and**

### ***Anaplasma marginale***

cross reactions with *T. vivax* ELISA,  
14092

**bio-economic model** 14210

### **biotechnology**

ethical, legal and social implications in  
Africa, 14184

### **Bolivia**

*T. vivax* in cattle, 14082

### **Botswana**

effects of deltamethrin spraying on bird  
populations, 14212

**bovine radiation hybrid map** 14238

### **Brazil**

- spatial distribution of *T. cruzi* and *T. evansi*, 14232
- T. vivax* antibody ELISA for .. trypanosomiasis in cattle, 14092
- Burkina Faso**
  - diffusion model for *G. p. gambiensis*, 14203
  - drug use by small-scale livestock keepers, 14239
  - mapping animal trypanosomiasis risk, 14206
  - parasites of camels, 14081
  - population structure of *G. p. gambiensis*, 14202
- Butyrospermum paradoxum* *see* drugs, natural products
- Cameroon**
  - blood parasites of chickens, 14079
  - HIV-1 group M retrovirus, 14055
  - trypanosomiasis and drug resistance, 14233
- cyclic adenosine monophosphate (cAMP)**
  - signalling 14268
  - transformation of *T. brucei* slender to stumpy forms, 14146
- card agglutination test for trypanosomiasis (CATT)**
  - for *T. evansi* in humans, 14056
  - for humans and animals, 14227
- cattle**
  - breeds
    - Boran, 14255
    - N'Dama, 14086, 14255
    - Zebu, 14234
  - diseases other than trypanosomiasis
    - Anaplasmosis, 14050, 14094
    - biting flies 14028
    - East Coast fever 14050
    - foot and mouth 14050
    - ticks 14030
    - West Nile virus 14023
- Chagas disease** *see* trypanosomiasis in humans (American)
- chromatography**
  - sample preparation for pesticides in Africa, 14186
- chromosomal nuclear positioning** *see* gene expression
- clades** 14286
- climate change** *see* vector-borne diseases, transmission
- Cochliomyia hominivorax* 14182
- combination chemotherapy** 14073, 14273 *see also* drugs
- comparative genomics** 14303
- Côte d'Ivoire**
  - genetic characterization of *T. brucei* s.l., 14289
  - populations of *G. p. palpalis*, 14208
- counterfeit products** *see* drugs
- Culicidae**
  - DNA barcodes, 14038 *see also* molecular characterisation
- Cussonia zimmermannii* *see* drugs, natural products
- cyclophosphamide** 14245
- cysteine protease inhibitors** *see* drugs,
- cytochrome transcripts** 14135
- cytoplasmic incompatibility** 14189
- DB289** 14021, *see* drugs
- deltamethrin**
  - effects on bird populations in Botswana, 14212
  - treatment of cattle, 14045
  - tsetse control using pyrethroid footbaths, 14041
- Democratic Republic of Congo**
  - civil conflict and sleeping sickness, 14047
  - costs of human trypanosomiasis in a rural community, 14072
  - human genetic diversity and susceptibility to human African trypanosomiasis, 14217
  - melarsoprol versus eflornithine treatment, 14064

- transmission of human trypanosomiasis, 14052
- treatment failure, IgM synthesis, CSF-IgM and IL-10, 14070
- differentiation**
  - long slender to short stumpy *T. brucei* using troglitazone, 14135
- difluoromethylornithine (DFMO)** *see* drugs, eflornithine and trypanosomiasis in humans
- diminazene aceturate** *see* drugs
- Djallonké sheep**
  - genetic and phenotypic parameters of bodyweight, 14087
- DNA**
  - polymorphisms
    - genes coding for cytokines, 14217
    - sequence data for *T. gallinarum* in chickens, 14079
    - mitochondrial cytochrome oxidase gene, 14038 *see* *Culicidae*
- dogs** *see* trypanosomiasis in dogs
- dromedary camels** *see* trypanosomiasis in camels
- drugs**
  - barriers to development, 14075, 14229
  - combination therapy, 14065, 14073, 14074, 14273
  - community participation in The Gambia, 14214
  - development of new drugs, 14031
  - discovery and comparative genomics, 14303
  - review of existing and pipeline drugs for human infections, 14229
  - productivity assessment of drugs by livestock keepers, 14239
  - strategies: targets versus targeting, 14071
  - training farmers in rational use, 14241
  - use of SRA gene to identify resistant isolates, 14288
  - targets
    - adenosine analogues, 14146
    - adenosine 3', 5' monophosphate signalling mechanisms, 14268
    - CTP synthetase, 14108
    - cysteine protease inhibitors, 14246
    - enolase, 14269
    - enzymes in spermidine synthesis, 14263
    - glycosome import pathway, 14138
    - nucleoside transport activities, 14128
    - phosphodiesterases, 14153
    - polyamine biosynthetic enzymes, 14156, 14164, 14262, 14263
    - pyridoxal 5'-phosphate enzymes, 14256
    - spermidine synthase, 14281
    - tRNA synthetases, 14314
    - trypanosome alternative oxidase, 14155
    - trypanothione reductase and synthetase inhibitors, 14110, 14112
- commercial trypanocides
  - diamidines
    - mechanisms of action, 14113
  - diminazene aceturate
    - resistance in Cameroon, 14233
    - resistance of *T. b. rhodesiense* isolates, 14230
  - diminazene diacetate
    - LC-MS for confirmation, 14121
  - eflornithine
    - efficacy compared with melarsoprol 14064
  - homidium chloride
    - control of counterfeit products using HPLC, 14242
    - metabolism in hepatocytes, 14107
    - sensitivity of *T. b. rhodesiense*, 14230
    - T. congolense* resistance and karyotype profiles, 14126
  - melarsamine hydrochloride
    - cross resistance between arsenical and diamidine drugs, 14260
  - melarsen oxide
    - sensitivity of *T. b. gambiense* isolates, 14291
  - melarsoprol
    - combined with eflornithine for treating *T. b. brucei*, 14074



combined with nifurtimox for treating *T. b. gambiense*, 14074  
 combined with substance P receptor antagonist, 14273  
 comparison with eflornithine for treating late stage Gambian trypanosomiasis, 14064  
 equivalence used alone or in combination with nifurtimox, 14065  
 induced encephalopathy, 14066, 14067  
 treatment of pre-school children, 14067  
 treatment of woman after African safari, 14061  
 sensitivity of *T. b. rhodesiense*, 14230  
 nifurtimox  
   combined with eflornithine for treating *T. b. gambiense*, 14074  
   introduction of, 14020  
   combined with melarsoprol for *T. b. gambiense* infections, 14065  
 pentamidium  
   in pre-school children, 14067  
   treatment against late stage *gambiense* infections, 14263  
   treatment failure, South Sudan, 14291  
   treatment of woman after African safari, 14061  
   treatment in Nigeria, 14227  
 pyrimethamine  
   review: chemotherapeutic strategies against *T. brucei*, 4071  
 suramin  
   distribution across the blood-brain and blood-CSF interfaces in mice, 14275  
   treatment failure and intrathecal IgM synthesis, 14070  
   treatment of black bears, 14085  
   treatment of woman after African safari, 14061  
 experimental trypanocides  
   acivicin, 14108  
   analogues of 5'-(methylthio)-adenosine, 14280  
   2, N6-disubstituted adenosine analogues, 14272  
   arsonoliposomes, 14284  
   bisbenzofuran cations, 14258  
   diazabicyclic tropolone derivatives, 14266  
   diphenyl furans and aza analogues, 14113  
   epimers of bicycle[2.2.2]octan-2-ol derivatives, 14277  
   5-fluoroucil, 14109  
   megazol derivatives, 14120  
   phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, 14274  
   piperazine-linked bisbenzamidines and bisbenzamidoxime, 14265  
   quaternary naphthalimide derivatives, 14116  
   quinuclidine derivatives, 14261  
 natural products  
   *Albizia zygias* stem bark against *T. b. rhodesiense*, 14118  
   *Annona senegalensis* leaf extract activity against *T. b. brucei*, 14119  
   *Butyrospermum paradoxum* stem bark against *T. brucei* and *T. congolense*, 14114  
   *Cussonia zimmermannii* polyacetylenes, 14278  
   *Holarrhena africana* fractions, 14270  
   *Landolphia uniflora* extracts, 14257  
   review: natural products as anti-trypanosomal drugs (American trypanosomiasis), 14282  
   *Strychnos spinosa* leaf triterpenoids and sterols, 14264  
 resistance  
   contributions of TbAT1 and TbMRPA, 14111  
   inhibitory drug concentrations using <sup>3</sup>H-hypoxanthine, 14240  
   mechanisms of resistance, 14020  
   multiple resistance of *T. b.*

*rhodesiense* 14230  
 panels of resistant reference strains, 14240  
 pentamidine transporter and cross-resistance between arsenical and diamidine drugs, 14260  
 pharmacokinetics  
 DB289 in rats and monkeys, 14115

**editosome** 14304, 14305

**electrospray liquid chromatography-mass spectrometry** 14121

**enzyme-linked immunosorbent assay (ELISA)**  
 detection of trypanosomiasis and anaplasmosis, 14094  
 IgY for host determination, 14046  
*T. vivax* detection, 14092

**epidemiology** *see also* transmission and trypanosomiasis in humans, animal hosts and tsetse  
 antibody response to salivary proteins as epidemiological tool, 14051  
 civil conflict, 14047  
*G. m. submorsitans* in the Ghibe River Valley, 14224  
 host genetics, 14217  
 host preferences, 14225  
 human genetic diversity, 14032  
 human practices, 14183  
 learning and tsetse host choice, 14048  
 livestock farmers' perception, 14050  
 parasitic and other transmissible diseases, 14032  
 roles of cattle, goats and pigs, 14053  
 role of season, 14226  
 socio-economic and cultural activities, 14220

**Edmund Sergent** 14218

**eflornithine** *see* drugs

**epimastigotes**

**Equatorial Guinea**  
 spatial and temporal variability of tsetse population in the Mbini focus, 14204

**equines** *see* trypanosomiasis in horses

**eradication**  
 optimisation of programmes, 14215  
 via age-structured culling, 14023

using SIT, 14176, 14182, 14202, 14211, 14215

**Ethiopia**  
 control of tsetse in southern Rift Valley, 14209  
 Ethiopia's fly factory, 14190  
 factory flies and wild flies, 14191  
 importance of *G. m. submorsitans*, 14224

**Field's stain** 14226

**fluorescent fragment length barcoding (FFLB)**  
 species identification of trypanosomes, 14285

**fluorescent markers** 14207

**functional genomics**  
 training centre in Africa, 14171

**genetically engineered vectors**  
 control of mosquitoes, 14185  
 energetic limitations of insects, *see Anopheles gambiae*

**genetics** *see also* trypanotolerance  
 diversity  
 biodiversity of CYP51 in trypanosomes, 14123  
 comparative phylogeography of *T. rangeli*, 14290  
 diversity of trypanosomes in field caught tsetse, 14216  
 diversity of trypanosome isolates to drugs, 14288  
 epidemiology of parasitic and other transmissible diseases, 14032  
 genetic characterisation of *T. brucei* s.l., 14289  
 genetic diversity in *Glossina pallidipes*, 14039  
 genetically differentiated populations of *G. p. palpalis*, 14208  
 genetic variability of *T. evansi*, 14125

genotypic and phenotypic characterisation of *T. b. gambiense* isolates, 14291

karyotype profiles of *T. congolense*, 14126

multiple displacement amplification for population genetic analysis, 14293

population genetic structure of *T. b. gambiense*, 14336

population structuring of *G. p. palpalis*, 14202

resolution of the species problem, 14138

susceptibility to human African trypanosomiasis, 14217

systematic strategy for large-scale analysis of genotype phenotype correlations, 14313

**genome**

amplification, 14150

evolution, 14035

**geographic information systems (GIS)**

optimisation of tsetse eradication programmes, 14215

area-wide control of insect pests, 14168

use in Ethiopia, 14209

**genetic characterisation**

amplified fragment length polymorphism (AFLP)

population structure of *T. b. gambiense*, 14336

cDNA library screening

characterisation of salivary proteins from tsetse, 14199

characterisation of *T. brucei* s.l., 14289

DNA barcodes

species identification of Indian mosquitoes, 14038

expressed sequence tags(EST)

genes related to trypanotolerance, 14086

fluorescent fragment length barcoding

identification of trypanosomes in Tanzania, 14216

identification of new trypanosome species, 14285

general review: resolving species problems, 14138

loop-mediated isothermal amplification (LAMP)

diagnosis of trypanosome infections, 14243

microsatellites

genetic variability of *T. evansi*, 14125

multiple displacement amplification (MDA)

detection and genotyping of trypanosome species, 14150, 14293

polymerase chain reaction (PCR)

detection of salivary gland hypertrophy virus, 14200

diagnosis of *T. congolense* in a dog, 14235

detection of *T. vivax* in cattle, 14082

evolution of host choice in Diptera, 14196

identification and diversity of trypanosome species in tsetse, 14216

inter-simple sequence repeat (ISSR) anchored PCR

genetic variability of *T. evansi* isolates, 14125

multiplex PCR

to distinguish *T. b. brucei* from *T. b. rhodesiense*, 14294

real time PCR

for detection of RNA editing, 14304

spliced leader gene (SL) intergenic sequences

phylogeography of *T. rangeli* and *Rhodinius*, 14290

identification of trypanosomes in wild tsetse 14127

using SRA gene to identify *T. b. rhodesiense* in cattle and warthogs, 14076

using SRA gene to detect *T. b. rhodesiense* in humans and domestic animals, 14288

combined with RFLP for diagnosis of livestock trypanosomiasis, 14053  
diagnosis of trypanosomiasis in cattle, 14234  
serial analysis of gene expression(SAGE) technology  
bovine transcriptome analysis, 14086

**geomatics** 14025

***Glossina austeni***  
control with protective netting, South Africa, 14042  
in Kenya, 14050  
strategy for area-wide control in South Africa, 14211

***Glossina brevipalpis***  
control with protective netting, South Africa, 14042  
in Kenya, 14050  
strategy for area wide control in South Africa, 14211

***Glossina fuscipes fuscipes***  
and *Wolbachia* infections, 14189  
host determination using IgY ELISA, 14046

***Glossina longipennis***  
responses to baited Nzi traps, 14043

***Glossina morsitans***  
characteristics of saliva, 14199

***Glossina morsitans centralis***  
metabolic rate, 14040

***Glossina morsitans submorsitans***  
age prevalence of *T. congolense* and *T. vivax* , 14221  
effects of guaiaicol and analogues, 14213, 14194  
expression of fat body genes after infection with *T. b. brucei*, 14194  
in Adamaoua region of Cameroon, 14233  
in eastern Zambia, 14234  
iron binding proteins, 14037  
responses to guaiaicol, 14044  
responses to baited Nzi traps 14043  
role in livestock trypanosomiasis in eastern Zambia, 14053  
transferrin expression, 14034  
vertebrate hosts in the Ghibe Valley, 14224

***Glossina pallidipes***  
control with insecticide treated cattle, 14045  
copulation behaviour, 14192  
critical thermal limits, 14197  
host determination using IgY ELISA, 14046  
in Kenya, 14050  
role of attacin in susceptibility to trypanosomes, 14195  
cuticular hydrocarbons, 14193  
effect of guaiaicol and analogues, 14213  
host preferences in Kenya, 14225  
in southern Rift Valley of Ethiopia, 14209  
inter-population variations in cuticular lipid mass and dessication rates, 14193  
polymorphic microsatellites, 14039  
refractoriness, 14195  
responses to baited Nzi traps, 14043  
responses to guaiaicol, 14044  
seasonal variations in Tanzania, 14226  
thermal tolerance, 14198

***Glossina palpalis gambiensi***  
allele frequencies, 14202  
control with pyrethroid foot baths, 14041  
diffusion model, 14203  
effect of *T. b. brucei* on head proteome, 14222  
population structure according to landscape fragmentation, 14202

***Glossina palpalis palpalis***  
alterations in CNS during infections with trypanosomes, 14222  
genetic structure of populations, 14208  
spatial and temporal variability of population, 14204

***Glossina swynnertoni***  
seasonal variations in Tanzania, 14226

***Glossina tachinoides***  
control with pyrethroid footbaths, 14041  
in Adamaoua region of Cameroon, 14233

**glycosylphosphatidylinositol (GPI) *see***

- also* immune response  
 anchored proteins of procyclic *T. brucei*,  
 14033  
 anchored VSG, 14251
- guaiacol**  
 repellancy to savannah tsetse 14044
- heat shock proteins** 14136
- Hippoboscoidea** 14197
- HIV-1 group M**  
 spread through blood sampling, 14055
- HLA polymorphism** 14032
- Holarrhena Africana** *see* drugs, natural products
- homidium chloride** *see* drugs, commercial trypanocides
- high pressure liquid chromatography (HPLC)**  
 control of potentially counterfeit isometamidium products, 14242
- human high density lipoprotein (HDL)**  
*see* immune response/innate immunity
- IFN-gamma** *see* immune response/ innate immunity
- IgM** *see* immune response/innate immunity
- immune response/innate immunity** *see also* pathogenesis of trypanosomiasis in humans and trypanotolerance  
 general reviews, 14105, 14252  
 humans  
 involvement of host genetics, 14217  
*T. b. rhodesiense*: elevated IgM in CSF 14061  
 role of macrophage-like (M) cells in parasite control and immunopathology, 14252  
 mice  
*T. brucei*: activation of VSG genes by recombination into expression sites, 14131  
*T. brucei*: antigenic variation and silent information regulator 2-related proteins, 14129  
*T. brucei*: antigenic variation: from silent to noisy VSG genes, 14148
- T. b. brucei*: apolipoprotein L-1 and trypanolysis, 14062
- T. brucei*: beta-d-glucosyl-hydroxymethyluracil (base J) function in regulation of antigenic variation, 14322
- T. brucei* : CpG oligodeoxy nucleotide enhanced innate resistance and acquired immunity, 14097
- T. brucei*: cysteine peptase inhibitor and virulence, 14334
- T. brucei*: gene conversion as essential mechanism for antigenic variation, 14250
- T. brucei*: GPI treatment reduces immunopathology, 14251
- T. brucei*: link between telomere growth and VSG switching rates, 14310
- T. b. brucei*: SRA transfected cells alter intracellular trafficking of TLF, 14104
- T. brucei*: telomere mode of VSG silencing, 14139
- T. brucei*: VSG gene silent archive, 14327
- T. brucei*: VSG repertoires are strain specific, 14321
- T. b. brucei* and *T. evansi*: interleukin- 12p70 necessary for resistance, 14244
- T. congolense*: control of nitric oxide synthase, 14247
- T. congolense*: macrophage-derived TNF crucial for NO-mediated killing, 14247
- T. congolense*: MHC class II immune responses and IL-10 function, 14103
- T. congolense*: paraoxanose 1 prolongs survival, 14096
- T. congolense*: protection with TGF

- beta1, 14099
- T. congolense* and *T. brucei*:  
restricted role of CD1d immune responses, 14102
- T. congolense*: role of regulatory T cells 14237
- T. evansi*: beta tubulin: .protection against *T. evansi*, *T. equiperdium* and *T. b. brucei*, 14098
- T. evansi*: IgM –mediated control, 14095
- T. evansi*: infection linked to lack of apolipoprotein L-1, 14063
- T. evansi* : limited VAT repertoire of single stock, 14106
- rats
- T. lewisi*: alpha2 macroglobulin prolongs infections, 14245
- IFN-gamma** *see also* immune response /innate immunity  
cell priming and inflammatory response, 14255
- IgM** *see* immune response/innate immunity
- immunoaffinity absorption** 14254
- India**  
human trypanosomiasis caused by *T. evansi*, 14056
- interleukin 10 (IL-10)** *see* immune response/innate immunity
- insecticides**  
mechanisms of resistance, 14179  
impregnated odour-baited targets, 14211  
insecticide pour-on for tsetse control .in Gambia, 14214  
risk assessment for personnel, 14178
- integrated pest management (IPM)** *see* area-wide integrated pest management
- interferon-gamma** *see* immune response/innate immunity
- International Plant Protection Convention (IPPC)** 14169
- introduced species** 14182
- isometamidium chloride** *see* drugs, commercial trypanocides
- Kenya**  
bloodmeal sources using IgY ELISA, 14046  
epidemiology of bovine trypanosomiasis, 14050  
host preferences by *G. pallidipes*, 14225  
influence of socio-economic and cultural activities on risk of rhodesian sleeping sickness, 14220  
socio-economic impact of camel trypanosomiasis, 14084  
*T. b. rhodesiense* in cattle and warthogs, 14076
- kinetoplastids** *see* heat shock proteins
- landscape fragmentation**, 14202
- Landolphia uniflora*** 14257
- linkage disequilibrium** 14089
- loop-mediated isothermal amplification (LAMP)** 14243
- lysosome** 14253
- magnetic resonance imaging** 14066
- malaria**  
transmission and human practices, 14183
- Malawi**  
trypanosomiasis in a soldier, 14058
- Mali**  
drug use by small scale livestock keepers, 14239  
training farmers in rational drug use, 14241  
mapping African animal trypanosomosis risk through landscape approach, 14206
- marker-assisted selection**  
for bovine trypanotolerance, 14086
- mark-release-recapture** 14203
- melarsamine hydrochloride** *see* drugs, commercial trypanocides
- melarsen oxide** *see* drugs, commercial

- trypanocides
- melarsoprol** *see* drugs, commercial trypanocides
- membrane potential** 14135
- microsatellite genotyping** *see* molecular characterisation
- microsomal elongase pathway (ELO)** for fatty acid synthesis in *T. brucei*, 14160
- Millennium Development Goals**
  - Chagas disease as constraint to achievement in Latin America, *see* trypanosomiasis in humans (American)
- mitochondrial markers** 14135
- mobile targets** 14211
- model simulations** climate-health, 14024
- molecular characterisation** *see* genetic characterisation
- molecular markers** *see* molecular characterisation
- mono-pyramidal traps** control of *G. p. palpalis* in Equatorial Guinea, 14204
- mosquitoes**
  - DNA barcodes, 14038
  - genetically engineered vectors, 14185
  - physiological fitness of free-living and laboratory-reared males, 14175
- multiple-criteria evaluation (MCE)**, prioritisation of tsetse control, 14215
- multiple displacement amplification (MDA)** *see* molecular characterisation
- multiplex PCR** *see* molecular characterisation
  
- Nagana** 14104
- natural products** *see* drugs
- natural killer (NK) cells**
- N'Dama** *see* cattle breeds and trypanotolerance
- neglected diseases** 14166
- Nepal**
  - trypanosomiasis in cattle, buffaloes and dogs, 14077
- nifurtimox** *see* drugs, commercial trypanocides
  
- Nigeria**
  - surveillance for human sleeping sickness, 14227
- nitric oxide** *see* immune response/innate immunity
  
- octenol**
  - baits for Nzi traps, 14043
- Oecomys mamorae** 14232. *see also* *T. vivax* and *T. evansi*
- ornithine decarboxylase (ODC)** inhibitor of DFMO, 14281, 14263 *see also* drugs
- packed cell volume** *see* anaemia
- P2 nucleoside transporter** 14272
- Pakistan**
  - T. evansi* in horses and camels 14080
- Pan African Tsetse and Trypanosomosis Eradication Campaign (PATTEC)**
  - impact of fragmentation of landscapes on tsetse population structure, 14202
- pentamidine** *see* drugs, commercial trypanocides
- permethrin** *see* insecticides, risk assessment for personnel, 14178
- peroxins**, 14137
- pest - free areas** 14169
- pest risk analysis** 14169
- phenotypic variation**
  - microarray and QTL data, 14313
- piperazine-linked bisbenzamidines** *see* drugs
- polyamine biosynthesis** *see* drug targets
- polymerase chain reaction** *see* molecular characterisation
- prodrug DB 289** *see* drugs, pharmacokinetics
- programmed cell death** 14163
- protective netting** 14042
- protein signatures** 14174

**pulsed field gel electrophoresis**

determining chromosome profiles,  
14126

**pyrethroid foot baths** 14041

**pyrimethamine** *see* drugs

**quantitative trait locus (QTL)** 14238

**quaternary naphthalimide derivatives**

*see* drugs, experimental trypanocides

**quinuclidine derivatives**

*see* drugs, experimental trypanocides

**real time polymerase chain reaction**

**(RT-PCR)** *see* molecular  
characterisation

**refractoriness**

role of humoral immune response,  
14195  
possible application of tsetse symbionts  
14189

**regulatory T cells (Tregs)**

suppression of type 1 inflammatory  
response, 14237

**Republic of the Congo**

melarsoprol versus eflornithine  
treatment, 14064

**reservoir hosts**

human sleeping sickness, 14227

**reverse genetics** 14195

**ribosomal DNA (rDNA)**

18S, 14287  
18S and 28S alpha, 14285

**ribosomal RNA (rRNA)**

ITS-1 region, 14127, 14216  
5S, 14319  
5.8S and 18S, 14243  
small subunit(SSU), 14286

**RNA editing** 14155, 14305

cytochrome c oxidase III, 14154  
RNA binding proteins, 14330  
structural integrity of editosomes, 14130  
substrate determinants, 14133  
using recombinant proteins, 14144

**RNA interference (RNAi)**

ablation of phosphodiesterases, 14153  
attacin repression by double stranded  
RNA, 14195  
delayed kinetoplast division, 14317  
deletion of acyl carrier protein and ..beta  
acyl carrier protein synthase, 14160  
of flagellum attachment tone protein,  
14340  
depletion of peroxins 5 and 7 and  
growth inhibition in bloodstream and  
procyclic *T. brucei*, 14137  
depletion of *T. brucei*  
mitochondrial.pre- mRNAs, 14145  
effects on nuclear RNA binding  
proteins, 14319  
for mutant induction, 14316  
growth of *T. brucei* in low iron medium,  
14324  
for tryptophanyl-tRNA synthetase  
silencing, 14314  
knockdown of *Glossina* transferrin  
transcripts, 106  
of polo-like kinases, 14317  
of zinc metalloprotease in *T. brucei*,  
14315  
silencing of *T. brucei* adenosine kinase,  
14325  
targeting *T. brucei* motile flagellar genes  
14132  
tetracyclin induced, 14281

**restriction fragment length  
polymorphism (RFLP)** *see* molecular  
characterisation

**salivary gland expression library** 14199

**satellites for epidemiology** 14167

**surface enhanced laser desorption**

**ionisation (SELDI)** 14174

**sentinel herd surveillance systems**

14078

**sequential aerosol technique (SAT)**

14211, 14086

**serial analysis of gene expression**

**(SAGE)** 14086



**sika deer** 14287

**silent information regulator 2 (Sir2)-related proteins or sirtuins** 14129

**skin features** *see* trypanosomiasis in humans

**sleeping sickness** *see* trypanosomiasis in humans

***Sodalis glossinidius***  
to improve SIT, 14189  
relation to endosymbiont of slender pigeon louse, 14205

**South Africa**  
control of livestock trypanosomiasis, 14042  
strategy for area-wide control of tsetse, 14211

**Southern Tsetse Eradication Project (STEP)** 14209

**Spain**  
natural infections of *Trypanosoma* spp. in wild rabbits, 14236

**species identification** *see* molecular characterisation and genetic diversity

**spermidine** *see* drugs, targets

**spliced-leader gene (SL)** 14290

**Sanitary and Phytosanitary Agreement (SPS)** 14169

**serum resistance associated gene (SRA)**  
*see also* immune mechanisms/innate immunity  
SRA-PCR for detection of *T. b. rhodesiense*, 14091  
characterisation of *T. b. rhodesiense* isolates from Tanzania, 14288

**sterile insect technique (SIT)** 14168, 14169, 14173, 14182, 14185, 14188, 14209, 14211 *see also* area-wide pest management

***Stomoxys***  
responses to baited Nzi traps 14028, 14043

***Strychnos spinosa***, *see* drugs, natural products

**substance P (SP)** 14273

**succinate dehydrogenase** 14135

**Sudan**  
genotypic and phenotypic characterization of *T. b. gambiense*, 14291  
isolation and propagation of *T. b. gambiense*, 14124  
*T. b. gambiense* treatment in pre-school children, 14067

**suppression subtractive hybridisation (SSH) libraries** 14194

**suramin** *see* drugs, commercial trypanocides

**surface enhanced laser desorption ionization (SELDI)** 14174

**surra** *see T. evansi*

**surveillance** *see* epidemiology

**symbionts** *see Sodalis, Wigglesworthia* and *Wolbachia*

**tabanids**  
control with Nzi traps, 14028  
responses to baited Nzi traps, 14043

**Tanzania**  
characterization of *T. b. rhodesiense*, 14288  
identification of trypanosome species in tsetse, 14216  
seasonal variation in human African trypanosomiasis, 14226  
PCR for species identification in tsetse, 14127

**targets** *see* drugs

**telomere**  
deletion and VSG silencing, 14139

**telomeric expression sites (ES)** 14310

**TGF-beta I** *see* immune response/innate immunity

**The Gambia**  
community participation in trypanosomiasis control, 14214

***Thrichomys pachyurus*** 14232

**transmission**  
alterations in arthropod vectors and vertebrate hosts, 14177  
antioxidants and establishment of

trypanosomes in tsetse, 14223  
 blocking vaccines, 14049  
 by fleas in wild rabbits, 14236  
 by transfusion, 14022, 14170  
 civil conflict, 14047  
 IgG response to saliva from tsetse, 14051  
 impacts of climate change, 14024  
 learning and host choice, 14048  
 parasite manipulation, 14177  
 skin as interface, 14021  
*T. evansi* in humans, 14056  
*T. vivax* and *T. evansi* in Brazilian Pantanal, 14232

**transmission risk**  
 socio-economic and cultural influences, 14220

**treatment/ treatment failure** *see* drugs

**trypanocides/ trypanocide resistance** *see* drugs

***Trypanosoma brucei*** *see also* drugs and immune response/innate immunity

- in cattle
  - Serengeti, Tanzania
  - in Uganda, 14091
- in goats
  - general review, 14038
- in warthogs
  - Serengeti, Tanzania
  - adenosine kinase, 14325
  - antigenic variation, 14129
  - antigenic variation and activation of VSG genes, 14131
  - aromatic amino acid catabolism, 14152
  - biodiversity of CYP51, 14123
  - CD1d immune responses in mice, 14102
  - cell cycle regulation, 14142
  - cell cycle stage specific markers, 14335
  - characterization of TFIIH homologue, 14147
  - conditional I-SceI meganuclease cleavage
  - deletion of a single telomere, 14139
  - CpG oligodeoxynucleotide treatment and innate resistance and acquired immunity of mice 14097
  - crystal structure of phosphofructokinase, 14149
  - CTP synthetase as drug target, 59
  - cysteine peptase inhibitor and differentiation and virulence, 14334
  - cytokinesis of bloodstream form, 14399
  - drug resistance, 14111
  - drug targets and drug targeting 14071
  - editosomes, 14305
  - endocytosis activation as adaptation to mammalian host, 14329
  - effect of cysteine protease inhibitors on cell morphology and division, 14159
  - effect of dihydroxyacetone, 14338
  - effect of GPI - based treatment of infections in mice, 14251
  - effects of 6-phosphogluconate dehydrogenase inhibitors, 14274
  - effect on TNF and IL-6 cytokines in infected mice, 14251
  - enolase as drug target, 14269
  - epimastigote forms, 14161
  - fatty acid synthesis, 14143
  - F-box protein mRNAs, 14318
  - flagellar adhesion and cell growth, 14337
  - flagellar motility, 14132
  - flagellum attachment zone filament structure, 14340
  - free GPI glycolipids, 14033
  - functional genomics, 14132
  - functions of RNA binding proteins, 14320
  - functions of zinc metalloprotease, 14315
  - gene conversion and antigenic variation, 14250
  - GPI- anchored proteins 14033
  - histone modifications, 14326
  - import of proteins into glycosomes, 14137
  - induction of cytokinesis defect, 14311
  - inhibition of oxygen uptake by KCN,

14135.  
 inhibitors of cysteine proteinases,  
 14159  
 intracellular iron utilization and  
 cellular morphology, 14324  
 lysosomal function and endocytosis,  
 14331  
 microsomal elongases and fatty acid  
 synthesis, 14143  
 migration across blood-brain barrier  
 in mice, 14249  
 mitochondrial fatty acid synthesis,  
 14160  
 mitochondrial gene expression, 14140  
 mitochondrial tRNA import, 14300  
 new membrane bound eukaryotic  
 initiation factor 2, 14328  
 novel phospholipases 14157  
 nuclear architecture and gene  
 expression, 14151  
 nucleoside transporter, 14128  
 phosphodiesterases, 14153  
 procyclin mRNAs of epimastigote  
 forms 14161  
 properties of spermidine synthase,  
 14281  
 pyrimidine transport 14109  
 regulation of telomeric DNA  
 glycosylation, 14322  
 purine salvage machinery, 14071  
 regulation of gene expression, 14151  
 GPI-based treatment  
 RNA editing, 14130, 14145  
 5S rRNA abundance and ribosomal  
 assembly, 14319  
 roles of cyclin in controlling cell  
 cycle progression, 14141  
 role of polo-like kinases, 14317  
 significance of tryparedoxin for  
 hydroxyperoxide detoxification,  
 14307  
 telomere deletion, 14139  
 telomere length, 14310  
 transformation of slender to stumpy  
 forms, 14146  
 troglitazone and differentiation,  
 14135

trypanothione reductase effects,  
 14112  
 tryptophanyl-tRNA synthetases  
 silencing, 14314  
 use of multiple displacement  
 amplification of DNA, 14150  
 VSG gene repertoires, 14321  
 VSG gene silent archive, 14327  
***Trypanosoma brucei brucei*** *see also*  
 immune response/innate immunity  
 alterations induced in head proteome  
 of tsetse vector, 14222  
 characterization of ecto-nucleoside  
 triphosphate diphosphohydrolase  
 activity, 14134  
 competition between strains in the  
 tsetse fly, 14207  
 discrimination from *T. b. rhodesiense*,  
 14294  
 effect of disubstituted adenosine  
 analogues, 14272  
 effect of extracts of *Landolphia*  
*uniflora*, 14257  
 effect of *H. africana* in infected mice,  
 14270  
 effect of human serum on lysosome,  
 14253  
 TLF killing, 14254  
 effect of piperazine-linked  
 bisbenzamidines, 14265  
 5-fluorouracil as potential trypanocide  
 14109  
 genes and iron metabolism, 14327  
 inhibition of cell death in tsetse,  
 14223  
 inhibition of growth and respiration  
 using inhibitors of alternative  
 oxidase, 14155  
 intracellular trafficking of host  
 immune response molecules, 14104  
 roles of haptoglobin related protein  
 and apolipoprotein L1 in  
 trypanolysis, 14062  
 role of IFN-gamma production in  
 resistance of mice, 14244  
 trypanosome maturation, 14049  
***Trypanosoma brucei gambiense*** *see also*

trypanosomiasis in humans, drugs and immune response/innate immunity

antibody IgG response to saliva from vectors and non-vectors, 14051  
diagnostic potential of TGSGP, 14312  
diagnosis using LAMP, 14243  
drug combinations in Uganda, 14074  
genetic diversity, 14289  
genotypic and phenotypic characterization, 14291  
human African trypanosomiasis in a rural community, 14072  
in pre-school children, 14067  
in tsetse midguts, 14052  
isolation and propagation, 14124  
population genetic structure using AFLP, 14336  
resistance to melarsamine hydrochloride, 14260  
role of endocrine disorders in infections, 14228  
skin features, 14059  
surveillance in Abraka focus, Nigeria, 14227  
treatment failure in Democratic Republic of Congo, 14070  
treatment with melarsoprol versus eflorinthine, 14064  
treatment with melarsoprol and nifurtimox, 14065  
use of SRA gene as marker to distinguish from *T. b. rhodesiense*, 14288

***Trypanosoma brucei rhodesiense*** *see also*  
trypanosomiasis in humans, drugs, immune response/innate immunity  
activity of root bark extracts of *Cussonia zimmermannii*, 14278  
characterization of isolates, 14288  
detection using SRA-associated gene, 14091  
effects of disubstituted adenosine

analogues, 14272  
effect of piperazine linked bisbenzamidines, 14265  
fevers, chills and rash after African safari, 14061  
*in vitro* effects of *H. africana*, 14270  
in cattle and warthogs, 14076  
in a soldier, 14058  
melarsoprol resistance, 14230  
multiple drug resistance, 14230  
treatment with melarsoprol, 14066

***Trypanosoma congolense*** *see also*  
trypanosomiasis in cattle, drugs and immune response/innate immunity  
in cattle  
Kenya, Zambia, 14050, 14053  
in pigs  
Zambia, 14053  
in a dog  
United Kingdom, 14235  
age prevalence in *G. m. morsitans*, 14221  
CD1d immune responses in mice 14102  
diagnosis using LAMP, 14243  
effect of GPI treatment on infection in mice, 14252  
effect of transforming growth factor on mice infections, 14099  
karyotype profiles, 14126  
MHC class II restricted immune responses in mice, 14103  
nitric oxide mediated killing in mice, 14247  
paraoxonase 1 in protection of mice, 14096  
resistance to isometamidium and role of apolipoprotein A-II and role of T cells in immune response of mice, 14237  
semen sialic acid and alpha -L-fucosidase levels in infected sheep, 14100  
trypanotolerance QTLs in mice, 14238

***Trypanosoma cruzi*** *see also*

- trypanosomiasis in humans (American) achieving the Millennium Development Goals, 14172
- aromatic amino acid catabolism, 14152
- diagnosis using LAMP, 14243
- donor testing for blood transfusions, 14171
- roles of IFN-gamma, nitric oxide and IgG in control, 14248
- spatial distribution in Brazilian Pantanal, 14232
- transmission by transfusion, 14022
- trend of vectors towards domesticity, 14165
- Trypanosoma equiperdum*** *see also* drugs activity of megalazol derivatives, 14120 reference strains for drug screening, 14240
- Trypanosoma evansi*** *see also* trypanosomiasis in humans, drugs and immune response/innate immunity antigen repertoire, 14106 apolipoprotein L-1, 14063 beta tubulin and protection against *T. evansi*, *T. equiperdum* and *T. brucei* in mice, 14098 effect of GPI treatment on infections in mice, 14252 genetic variability, 14125 in Himalayan black bears, 14085 in horses and camels in Punjab region, 14080 in humans in India, 14056 oxidative stress in rats, 14101 reference strains for drug screening, 14240 role of IFN-gamma in resistance of mice, 14244 role of IgM in immunity of mice, 14095 spatial distribution in Brazilian Pantanal, 14232 TNF, gamma interferon and nitric oxide in infected animals, 14095 use of monoclonal antibody for detection in horses, 14093 VAT repertoire, 14106
- Trypanosoma vivax*** in cattle Kenya epidemiology, 14050 prevalence in Bolivia, 14082 age prevalence in *G. m. morsitans*, 14221 detection of antibodies using ELISA, 14092 leaving group activation in nucleoside hydrolase, 14298 trypanosome CTP synthetase as drug target, 14108
- Trypanosoma gallinarum*** in chickens in Uganda and Cameroon, 14079
- Trypanosoma lewisi*** activity of alpha 2 macroglobulin in infected rats, 14245
- Trypanosoma pacifica*** multiplication in English sole, 14301
- Trypanosoma pleuronectidium*** in cod, 14122
- Trypanosoma rangeli*** phylogeny using polymorphism of spliced leader gene, 14290
- Trypanosoma theileri*** energy metabolism in bloodstream forms, 14339
- trypanosome lytic factor (TLF)** *see* immune response/innate immunity
- trypanosomiasis in black bears** clinical features and treatment, 14085
- trypanosomiasis in buffaloes** prevalence in Makwanpur district Nepal, 14077
- trypanosomiasis in camels** prevalence in the Punjab region Pakistan, 14080 review: parasites of camels, 14081 socio-economic impact, 14084
- trypanosomiasis in cattle** countries

Burkina Faso, 14041, 14239  
 Bolivia, 14082  
 Brazil, 14092, 14232  
 Cameroon, 14233  
 East Africa, 14210  
 Ethiopia, 14209  
 Kenya, 14050  
 Mali, 14239, 14241  
 Nepal, 14077  
 Pakistan, 14080  
 South Africa 14042, 14211  
 Tanzania, 14076  
 Uganda, 14091  
 The Gambia, 14214  
 Zimbabwe, 14045  
 Zambia, 14215, 14227, 14234

**control**  
 area-wide control, 14211  
 detecting anaemia and improving  
 treatment, 14215  
 investments in pour-on insecticides  
 and drugs, 14214  
 management of tsetse and bovine  
 infections, 14210  
 pyrethroid footbaths, 14041  
 protective netting, 14042  
 restricted application of insecticides,  
 14045, 14209  
 risk and drug resistance, 14233  
 training farmers in rational drug use  
 14241  
 treatment by small-scale livestock  
 keepers, 14239

**diagnosis**  
 development and use of an ELISA for  
 epidemiological surveys, 14092  
 diagnosis by amplification of the SRA  
 gene, 14091

**epidemiology**  
 epidemiology in Kwalé district, 14050  
 GIS and multiple criteria evaluation  
 for optimisation of eradication,  
 14215  
 prevalence in the Bolivian Pantanal,  
 14082  
 prevalence in the Ghibe Valley,  
 14227

prevalence in Makwanpur district,  
 14077  
 prevalence in the Serengeti, 14076

role in the epidemiology of livestock  
 trypanosomiasis in Zambia, 14227  
 spatial distribution in the Brazilian  
 Pantanal, 14232  
 immunity/innate resistance  
 comparative genome analysis of  
 trypanotolerance QTL, 14238  
 improving accuracy of selection for  
 trypanotolerance, 14088  
 transcriptome analysis, 14086

**trypanosomiasis in chickens**  
 prevalence in Uganda and Cameroon,  
 14079

**trypanosomiasis in deer**  
 isolation, 14287

**trypanosomiasis in dogs**  
 clinical signs and diagnosis, 14235  
 prevalence, 14077

**trypanosomiasis in fish** 14301, 14122

**trypanosomiasis in goats**  
 genetic and phenotypic parameters of  
 body weight in West African Dwarf  
 goats, 14087  
 global status, 14083

**trypanosomiasis in horses**  
 diagnosis of *T. evansi* using ELISA,  
 14093  
 prevalence in the Punjab region, 14080

**trypanosomiasis in humans (African)**  
 countries  
 Burkina Faso, 14289  
 Côte d'Ivoire, 14289  
 Democratic Republic of Congo,  
 14051, 14052, 14064, 14070,  
 14072, 14075  
 India, 14056  
 Kenya, 14046, 14061, 14220, 14225,  
 14230  
 Malawi, 14058  
 Nigeria, 14227  
 Sudan 14067, 14291  
 Tanzania, 14061, 14226, 14288  
 Uganda, 14047, 14230

14069, 14091, 14074  
 clinical features/ pathogenesis  
 anorexia, 14228  
 animal models, 14026  
 chancre, 14058  
 erythema, 14058  
 elevated CSF IgM , 14061  
 encephalopathy, 14065, 14066, 14067  
 fever, 14058, 14061  
 hypotension, 14228  
 interleukin-10, 14061  
 intrathecal IgM synthesis, 14070  
 lymphadenopathy, 14058  
 microhaemorrhages, 14066  
 role of endocrine disorders in *T. b. gambiense* infections  
 skin features, rash 14059, 14061  
 diagnosis  
 development of LAMP, 14243  
*T. b. rhodesiense* 14091  
*T. evansi* in India, 14056  
 epidemiology  
 civil conflict, 14047  
 divergence between east and west  
 Africa, 14027  
 human/vector relationships, 14051  
 influence of socio-economic and cultural factors on risk of  
 Rhodesian sleeping sickness,  
 14220  
 role of human genetic diversity,  
 14032  
 seasonal variations, 14226  
 surveillance in Abraka focus, 14227  
 transmission in Kinshasha, 14052  
 transmission risk of Rhodesian  
 sleeping sickness, 14225  
 bloodmeal sources using IgY ELISA  
 in Kenya , 14046  
 immune response/innate immunity  
 involvement of host genetics, 14217  
 trypanolysis and apolipoprotein L-1,  
 14062, 14063  
 isolate characterisation  
*T. b. rhodesiense*, 14288  
*T. brucei*, s.1 14289  
*T. b. gambiense*, 14291  
 treatment *see also* drugs  
 animal models 14026  
 barriers to drug development, 14075,  
 14229  
 causes & mechanisms of drug  
 resistance, 14020  
 challenges of chemotherapy, 14229  
 chemotherapeutic strategies, 14071  
 combination therapy, 14065, 14073,  
 14074, 14273  
 costs, 14072  
 development of new drugs, 14031  
 diamidines, 14113  
 diminazine aceturate, 14230, 14233  
 discovery and comparative genomics,  
 14303  
 melarsamine hydrochloride, 14260  
 melarsen oxide, 14291  
 melarsoprol, 14061, 14064, 14065,  
 14067, 14074, 14230, 14273  
 multiple drug resistance in *T. b. rhodesiense* isolates, 14230  
 nifurtimox, 14020, 14065, 14074  
 pentamidium, 14061, 14067, 14227,  
 14263, 14291  
 public-private partnerships, 14069  
 pyrimethrine, 14071  
 review: existing and pipeline drugs  
 for human infections, 14229  
 strategies: targets versus targeting,  
 14071  
 toxicity and cost, 14075  
 resistance of *T. b. rhodesiense*  
 isolates, 14230  
 suramin, 14061, 14070, 14275  
**trypanosomiasis in humans (American)**  
 human genetic diversity and  
 epidemiology, 14032  
 impediment to achieving the  
 Millennium Development Goals in  
 Latin America, 14172  
 links with human rights violations,  
 14166  
 overview: new natural product-based  
 drugs, 14282  
 transmission by transfusion, 14022  
**trypanosomiasis in mice** *see also* under

- trypanosome species
- Trypanosoma brucei*:
- CD1d immune responses, 14102
  - CpG oligodeoxynucleotide
    - treatment and innate resistance and acquired immunity, 14097
  - effect of GPI - based treatment of infections, 14251
  - effect on TNF and IL-6 cytokines, 14251
  - migration across blood-brain barrier, 14249
  - transformation of slender to stumpy forms, 14146
  - VSG gene repertoires, 14321
  - VSG gene silent archive, 14327
- Trypanosoma brucei brucei*:
- activity of *H. africana*, 14270
  - role of IFN-gamma production in resistance, 14244
  - trypanosome maturation, 14049
- Trypanosoma congolense*:
- effect of GPI treatment, 14252
  - effect of transforming growth factor, 14099
  - MHC class II restricted immune responses, 14103
  - nitric oxide mediated killing, 14247
  - paraoxonase 1 in protection, 14096
  - resistance to isometamidium and role of apolipoprotein A-II and role of T cells in immune response, 14237
  - trypanotolerance QTLs, 14238
- Trypanosoma evansi*:
- immunisation with beta tubulin, 14098
  - effect of GPI treatment, 14252
  - role of IFN-gamma in resistance, 14244
  - role of IgM in immunity, 14095
- trypanosomiasis in rabbits**
- natural infection rates in wild animals, 14236
- trypanosomiasis in rats**
- antioxidant status and *T. evansi* infections, 14101
- trypanosomiasis in sheep**
- semen sialic acid and modulation of alpha-L-fucosidase activity, 14100
- trypanotolerance**
- genes, 14086
  - QTL, 14238
  - role of T cells, 14237
  - selection of bulls 14088
  - selection in sheep and goats, 14087
  - genome analysis, 14238
- tsetse** *see also* under different *Glossina* species
- control
    - area-wide, 14173, 14209, 14211
    - baited Nzi traps, 14043
    - eco-social analysis of management, 14210
    - genetically-engineered insects, 14185
    - GIS and multiple criteria evaluation for optimising eradication, 14215
    - insecticide treated cattle 14045
    - protective netting, 14042
    - pyrethroid footbaths, 14041
    - repellency of 4-alkyl-substituted analogue of guaiacol, 14213
    - using symbionts, 14189
  - distribution, ecology, behaviour and population studies
    - copulation behaviour, 14192
    - diffusion model, 14203
    - genetically distinct populations, 14208
    - learning and host choice, 14048
    - mapping densities: landscape approach, 14206
    - population dynamics modelling 14040
    - population structuring, 14202
    - seasonal variations in population, 14226
    - spatial and temporal variability of populations, 14204
  - physiology and biochemistry
    - characteristics of saliva, 14199



- critical thermal limits, 14198
- lipid mass and desiccation, 14193
- metabolic rate, 14040
  
- molecular characteristics of iron binding proteins, 14037
- molecular aspects of transferrin expression, 14034
- thermal tolerance, 14197
- tsetse-host interactions
  - alterations in head proteome induced by trypanosome infection, 14222
  - antioxidants and establishment of trypanosomes, 14223
  - epizootiological importance in Ghibe Valley, 14224
  - expression of fat body genes after infection with trypanosomes, 14194
  - GPI-anchored proteins, GPI glycolipids and colonisation by trypanosomes, 14033
  - host determination using an egg yolk (IgY) ELISA, 14046
  - host preference, 14225
  - manipulation by trypanosomes, 14147
  - refractoriness, 14195
  - trypanosome maturation, 14049
  
- Uganda**
  - detection of *T. b. rhodesiense* using SRA-PCR 14091
  - human sleeping sickness and civil conflict, 14047
  - private-public partnerships for sleeping sickness control, 14069
  - treatment of human infections with drug combinations 14074
- United Kingdom**
  - trypanosome infection in a dog, 14235
- vector**
  - control campaigns
  - mapping tsetse densities, 14206
  - management
  - empowering farmers in integrated vector management, 14187
  - risk assessments for exposure to insecticides, 14178
- vector-borne disease**
  - early warning 14167
  - eradication via age-structured culling 14023
  - genetically engineered vectors, 14185
  - human practices and malaria transmission, 14183
  - impacts of climate change/ warming 14025, 14029
  - parasitic manipulations, 14177
  - vertical transmission, 14181
  - vectorial transmission, 14218
  - sentinel surveillance systems, 14078
- variant surface glycoprotein (VSG)** *see also* immune response/innate immunity
  - exchange to procyclin during differentiation 14334
  - gene silent archive, 14327
  - release from procyclic trypanosomes, 14315
  - sequence divergence between trypanosome strains, 14321
- warthog**
  - host for *G. m. submorsitans* and *G. pallidipes*, 14224
- West African Dwarf goat** 14087
  - genetic and phenotypic parameters of bodyweight, 14087 *see* trypanotolerance
- Wigglesworthia glossinidia brevipalpis** *see* symbionts
- Wolbachia**
  - and cytoplasmic incompatibility, 14189
- working oxen and equids**
  - health and husbandry improvements, 14180
- Zambia**
  - age prevalence of trypanosomes in female *G. m. morsitans*, 14221
  - role of cattle, goats and pigs in epidemiology of livestock

- trypanosomiasis, 14053
- trypanosomosis incidence in cattle, 14234
- MCE for tsetse control
  - prioritisation, 14215
- temperature tolerance of *G. pallidipes*, 14198
- Zimbabwe**
  - deltamethrin treatment of cattle, 14045